#ACR25 Please find my video interview with Prof Edward Vital @edvital on their work on International Consensus of Glucocorticoid Tapering Guideline in #SLE #lupus Abstr#1526 @RheumNow https://t.co/MnQdcdASkG https://t.co/b7GMcnFU2m

• Putting Steroid Tapering into Practice in SLE
• https://x.com/Yuz6Yusof/status/1983151495173550130/photo/1

Management of cardiac and joint sarcoidosis. Use of TNFi in treatment refractory cases. Alana Nevares-Berrios @RheumNow #ACR25 https://t.co/hXOfkgQHP9

• https://x.com/synovialjoints/status/1983151209369206924/photo/1
• https://x.com/synovialjoints/status/1983151209369206924/photo/1

#ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumomab in #SLE @RheumNow https://t.co/5JrLG41nsD https://t.co/KeY6AkHUNK

• Progressive BiTE in SLE 2
• https://x.com/Yuz6Yusof/status/1983150449952768008/photo/1

#ACR25 Please find my video and take on Abstr#0803. Should we use Belimumab before- or after a trial of concentional immunosuppressant in #SLE? @RheumNow https://t.co/ExIvrdJXw5 https://t.co/AVb5ohWwXZ

• Belimumab Before or After Immunosuppressant | RheumNow
• https://x.com/Yuz6Yusof/status/1983149200066904516/photo/1

SLGT-2 and GLP-1 in RA: More than Weight Loss https://t.co/SRKMHNlHZo Future of rheumatology is bright , Shreya Sakthivel discussed her work on TriNetX database , looking specifically for effect of SLGT-2. GLP-1 on RA flare incidence. @RheumKay @RheumNow #acr25

• SLGT-2 and GLP-1 in RA: More than Weight Loss

GLP-1 in Knee Osteoarthritis https://t.co/SxyVEAK1CZ @bella_mehta Discusses role of GLP1 in OA and possible mechanisms of effectiveness ? weight reduction ? or doses it have anti-inflammatory -anti-fibrotic role ? @RheumNow #ACR25

• GLP-1 in Knee Osteoarthritis

Progressive BiTE in SLE 2 https://t.co/ykMQmSAdlb More on BiTES in SLE by the one and only @Yuz6Yusof Bi specific Tcell engager ( CD3-CD19). @RheumNow #ACR25

• Progressive BiTE in SLE 2

New Paradigms in RA Treatment https://t.co/CqpI2znglE @jeffsparks Highlights new trials in RA 1-Neuro immune modulation ( Vagal nerve stimulation). 2-Targeting pathogenic T cells 3-T reg CAR-T ( Peace maker). @RheumNow #ACR25

• New Paradigms in RA Treatment

Day 2 Recap: ACR Convergence 2025 Highlights https://t.co/b8XvrEsoLW Such a great time to be a rheumatologist. Fake rheumatology sounds like a great topic! Daily challenges and unusual presentations. @DrMiniDey @synovialjoints @drdavidliew @RheumNow #ACR25

• Day 2 Recap: ACR Convergence 2025 Highlights

#ACR25 Abstr#0855 Five extra patients were added to complete IMPACT Open Label Phase 2 trial of add-on Certolizumab in APS women + LAC+ve. Results stood: primary endpoint was met (adverse pregnancy outcome=19.6%; lower than 20% expected). Significant enough to adopt @RheumNow https://t.co/zhFVGYXiaU

• https://x.com/Yuz6Yusof/status/1982989650701758665/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

#ACR25 Day 1 RECAP Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1. https://t.co/js5FVBvUfk https://t.co/smh1AyPhfa

• ACR2025 Day 1 RECAP | RheumNow